Breast Cancer Recurrence Risk High After Stopping Endocrine Therapy at 5 Years

Submitted by admin5 on Tue, 11/21/2017 - 14:33

Administering endocrine therapy for 5 years significantly reduces recurrence rates during and after treatment for patients with early-stage, ER-positive breast cancer. Continuing to administer therapy after 5 years may offer further protection against recurrence, but is associated with additional side effects. Further research on the absolute risk of subsequent distant recurrence if therapy stops at 5 years would help physicians determine whether or not to extend treatment.

Daniel F Hayes, MD, Stuart B Padnos Professor of Breast Cancer Research, University of Michigan Comprehensive Cancer Center, and colleagues conducted a meta-analysis of the results of ER-positive breast cancer trials that tested endocrine therapy. A total of 88 trials involving 62,923 patients were analyzed. Kaplan-Meier and Cox regression analyses were utilized to evaluate the associations between tumor diameter and nodal status (TN), tumor grade, and other factors with patient outcomes during the period from 5 to 20 years after endocrine therapy had stopped.

Researchers found that breast cancer recurrence occurred steadily throughout the 5 to 20-year period. Risk of distant recurrence was significantly associated with original TN status. Among patients with stage T1 cancer, risk of distant recurrence was 13% with no nodal involvement, 20% with one to three nodes involved, and 34% with four to nine nodes involved. Similarly, patients with stage T2 disease were subject to risks of 19%, 26%, and 41%, respectively.


Related Content

Adding a statin to endocrine therapy tied to improved breast cancer outcomes

Disparities in adjuvant endocrine therapy for breast cancer identified


Furthermore, Dr Hayes and colleagues found that during the study period, the absolute risk of distant recurrence among patients with stage T1 disease and no nodal involvement was 10% for low-grade cancer, 13% for moderate-grade cancer, and 17% for high-grade cancer. Corresponding risks of any recurrence or a contralateral breast cancer were 17%, 22%, and 26%, respectively.

Researchers concluded that from 5 to 20 years after endocrine therapy stopped for patients with early-stage, ER-positive breast cancer, recurrence continued to occur steadily. Risk of distant recurrence was significantly correlated with the original TN status, with risks ranging from 10% to 41% depending on TN status and tumor grade, they wrote.  

"These data can be used by patients and their health care providers as they consider whether to continue taking anti-estrogen therapy beyond five years, weighed against side effects and toxicity of the therapies," Dr Hayes commented (November 8, 2017).—Zachary Bessette